Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

and rash (2.1% each). Kopetz said the global phase III, randomized KRYSTAL-10 trial has completed enrollment and will compare the combination of adagrasib and cetuximab versus FOLFIRI or mFOLFOX6 ...

The therapy combines Krazati (adagrasib) and cetuximab and is approved for patients ... The approved combination targets a specific mutation in the KRAS gene, known as G12C. This mutation is ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

RAS mutations impair the ability of RAS to convert ... in a Phase 1 clinical trial as monotherapy and in combination with cetuximab; QTX3046, a G12D-selective KRAS inhibitor, currently in a ...